Last reviewed · How we verify
GSK573719/VI 125/25
GSK573719/VI 125/25 is a LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
GSK573719/VI 125/25 is a combination of an inhaled long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease.
GSK573719/VI 125/25 is a combination of an inhaled long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | GSK573719/VI 125/25 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) |
| Target | M3 muscarinic receptor and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
GSK573719 (umeclidinium) is a LAMA that blocks muscarinic M3 receptors on airway smooth muscle, while VI 125/25 refers to vilanterol, a LABA that activates beta-2 adrenergic receptors. Together, these agents produce complementary bronchodilation through different mechanisms, improving lung function and reducing symptoms in COPD patients. The combination is delivered via dry powder inhaler for once-daily dosing.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Nasopharyngitis
- Cough
Key clinical trials
- Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component (PHASE2)
- Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (PHASE2)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
- Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study. (PHASE1)
- Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses (PHASE1)
- A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719/VI 125/25 CI brief — competitive landscape report
- GSK573719/VI 125/25 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK573719/VI 125/25
What is GSK573719/VI 125/25?
How does GSK573719/VI 125/25 work?
What is GSK573719/VI 125/25 used for?
Who makes GSK573719/VI 125/25?
What drug class is GSK573719/VI 125/25 in?
What development phase is GSK573719/VI 125/25 in?
What are the side effects of GSK573719/VI 125/25?
What does GSK573719/VI 125/25 target?
Related
- Drug class: All LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) drugs
- Target: All drugs targeting M3 muscarinic receptor and beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: GSK573719/VI 125/25 vs similar drugs
- Pricing: GSK573719/VI 125/25 cost, discount & access